This bill was referred to these committees:
- Showing contributions
- Jan 2001-Oct 2008 Senate / Jan 2003-Oct 2008 House
House Committee on Energy and Commerce
Contributions received from interests who:
Legislator | Party | State | Did want this law | Did not want this law | ||
|---|---|---|---|---|---|---|
| Dingell (Chair) | D | (MI-15) | $138,900 | $256,100 | (details…) | |
| Barton (Ranking Member) | R | (TX-6) | $15,750 | $308,250 | (details…) | |
| Allen | D | (ME-1) | $118,800 | $26,900 | (details…) | |
| Baldwin | D | (WI-2) | $112,858 | $13,500 | (details…) | |
| Barrow | D | (GA-12) | $169,550 | $42,550 | (details…) | |
| Blackburn | R | (TN-7) | $5,000 | $93,450 | (details…) | |
| Blunt | R | (MO-7) | $37,119 | $197,500 | (details…) | |
| Bono Mack | R | (CA-45) | $16,250 | $17,250 | (details…) | |
| Boucher | D | (VA-9) | $106,050 | $76,655 | (details…) | |
| Burgess | R | (TX-26) | $33,600 | $138,500 | (details…) | |
| Butterfield | D | (NC-1) | $80,750 | $23,335 | (details…) | |
| Buyer | R | (IN-4) | $17,500 | $165,750 | (details…) | |
| Capps | D | (CA-23) | $136,299 | $22,100 | (details…) | |
| Cubin | R | (WY) | $71,500 | (details…) | ||
| Deal | R | (GA-9) | $24,250 | $206,169 | (details…) | |
| DeGette | D | (CO-1) | $72,250 | $80,772 | (details…) | |
| Doyle | D | (PA-14) | $127,700 | $22,300 | (details…) | |
| Engel | D | (NY-17) | $89,000 | $57,000 | (details…) | |
| Eshoo | D | (CA-14) | $49,500 | $227,792 | (details…) | |
| Ferguson | R | (NJ-7) | $16,450 | $501,027 | (details…) | |
| Fossella | R | (NY-13) | $2,000 | $30,000 | (details…) | |
| Gonzalez | D | (TX-20) | $68,000 | $14,550 | (details…) | |
| Gordon | D | (TN-6) | $109,100 | $50,000 | (details…) | |
| Green | D | (TX-29) | $126,250 | $23,600 | (details…) | |
| Hall | R | (TX-4) | $3,000 | $28,826 | (details…) | |
| Harman | D | (CA-36) | $26,700 | $2,500 | (details…) | |
| Hill | D | (IN-9) | $157,005 | $43,754 | (details…) | |
| Hooley | D | (OR-5) | $136,000 | $10,000 | (details…) | |
| Inslee | D | (WA-1) | $89,250 | $88,965 | (details…) | |
| Markey | D | (MA-7) | $68,050 | $16,900 | (details…) | |
| Matheson | D | (UT-2) | $72,756 | $122,252 | (details…) | |
| Matsui | D | (CA-5) | $86,900 | $11,750 | (details…) | |
| Melancon | D | (LA-3) | $163,000 | $46,999 | (details…) | |
| Murphy | R | (PA-18) | $44,250 | $146,100 | (details…) | |
| Myrick | R | (NC-9) | $96,249 | (details…) | ||
| Pallone | D | (NJ-6) | $211,761 | $106,050 | (details…) | |
| Pickering | R | (MS-3) | $6,500 | $105,725 | (details…) | |
| Pitts | R | (PA-16) | $4,000 | $95,749 | (details…) | |
| Radanovich | R | (CA-19) | $5,500 | $5,000 | (details…) | |
| Rogers | R | (MI-8) | $24,000 | $164,010 | (details…) | |
| Ross | D | (AR-4) | $122,750 | $9,850 | (details…) | |
| Rush | D | (IL-1) | $66,500 | $39,500 | (details…) | |
| Schakowsky | D | (IL-9) | $148,150 | $8,175 | (details…) | |
| Shadegg | R | (AZ-3) | $500 | $41,000 | (details…) | |
| Shimkus | R | (IL-19) | $33,500 | $70,450 | (details…) | |
| Solis | D | (CA-32) | $119,000 | $37,250 | (details…) | |
| Stearns | R | (FL-6) | $1,500 | $51,204 | (details…) | |
| Stupak | D | (MI-1) | $146,524 | $11,500 | (details…) | |
| Sullivan | R | (OK-1) | $500 | $39,447 | (details…) | |
| Terry | R | (NE-2) | $6,500 | $27,063 | (details…) | |
| Towns | D | (NY-10) | $60,875 | $168,785 | (details…) | |
| Upton | R | (MI-6) | $31,300 | $119,550 | (details…) | |
| Walden | R | (OR-2) | $5,500 | $66,603 | (details…) | |
| Waxman | D | (CA-30) | $99,500 | $79,100 | (details…) | |
| Weiner | D | (NY-9) | $35,000 | $2,501 | (details…) | |
| Whitfield | R | (KY-1) | $31,100 | $106,184 | (details…) | |
| Wilson | R | (NM-1) | $12,200 | $46,386 | (details…) |
Contribution data provided by the Center for Responsive Politics (OpenSecrets.org)
Comments 
Lower Drug Prices for Medicare Participants by Milan Sundaresan, Jul 31, 2008 (7:41pm)
H.R. 4 allows the federal government to negotiate lower drug prices with pharmaceutical companies for Medicare members. Clearly the bill garnered support from various workers’ unions but was opposed by larger pharmaceutical companies.
Latest Comments
See More | New Comment